Vicore Pharma AB
- Country
- 🇸🇪Sweden
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://vicorepharma.com
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 270
- Registration Number
- NCT06588686
- Locations
- 🇲🇽
Integral Health Medical Unit, San Nicolás De Los Garza, Mexico
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 11
- Registration Number
- NCT05831644
- Locations
- 🇸🇪
Skånes universitetssjukhus, Malmö, Sweden
A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers
- Conditions
- Drug Interaction
- Interventions
- Drug: Drug Drug Interaction
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 19
- Registration Number
- NCT05830799
- Locations
- 🇸🇪
CTC Clinical Trial Consultants AB, Uppsala, Sweden
First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects
- Conditions
- ToleranceIdiopathic Pulmonary FibrosisPulmonary HypertensionSafety Issues
- Interventions
- Drug: PlaceboDrug: C106 solution
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 80
- Registration Number
- NCT05427253
- Locations
- 🇸🇪
CTC Clinical Trial Consultants AB, Uppsala, Sweden
Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF
- Conditions
- Pulmonary FibrosisAnxiety
- Interventions
- Device: Digital cognitive behavioral therapy
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 108
- Registration Number
- NCT05330312
- Locations
- 🇺🇸
Curebase Study Site, San Francisco, California, United States
🇺🇸University of Utah Health, Salt Lake City, Utah, United States
Effect of C21 on Forearm Blood Flow
- Conditions
- Study Vasodilatory Effects of C21
- Interventions
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 5
- Registration Number
- NCT05277922
- Locations
- 🇸🇪
Clinical Trial Consultants AB, Uppsala, Uppsala Lân, Sweden
A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 272
- Registration Number
- NCT04880642
- Locations
- 🇵🇭
West Visayas State University Medical Center, Iloilo City, Philippines
🇺🇸Parkview Physicians Group - Infectious Diseases, Fort Wayne, Indiana, United States
🇺🇦Regional Clinical Hospital of Infectious Diseases, Kharkiv, Ukraine
Retrospective Evaluation of Lung Pathology in Subjects With COVID-19
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 39
- Registration Number
- NCT04878913
- Locations
- 🇮🇳
First Floor Clinical Research Department Rhythm Heart Institute, Vadodara, Gujarat, India
🇮🇳Department of Medicine, Government Medical College and Hospital, Nagpur, Maharashtra, India
🇮🇳Department of Medicine, Civil Hospital and B J Medical College, Ahmadabad, Gujarat, India
Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 52
- Registration Number
- NCT04533022
- Locations
- 🇮🇳
N. K. P. Salve Institute of Medical Sciences & Research Centre and Lata Mangeshkar Hospital, Nagpur, Maharashtra, India
🇮🇳Ace Hospital & Research Center, Pune, Maharashtra, India
🇮🇳Hindusthan Hospital, Coimbatore, Tamilnadu, India
Safety and Efficacy of C21 in Subjects With COVID-19
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 206
- Registration Number
- NCT04452435
- Locations
- 🇮🇳
Department of Medicine, Civil Hospital and B J Medical College, Ahmadabad, Gujarat, India
🇮🇳First Floor Clinical Research Department Rhythm Heart Institute, Vadodara, Gujarat, India
🇮🇳Infectious Disease, Metas Adventist Hospital, Surat, Gujarat, India